Skip to main content

Drug Interactions between bedaquiline and oritavancin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

bedaquiline oritavancin

Applies to: bedaquiline and oritavancin

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to the major N-monodesmethyl metabolite, M2. Because M2 is 4- to 6-fold less active than the parent drug in terms of antimycobacterial potency, the interaction may diminish the therapeutic effect of bedaquiline. In healthy volunteers, administration of a single 300 mg dose of bedaquiline in combination with the potent CYP450 3A4 inducer rifampin (600 mg once daily for 21 days) reduced bedaquiline systemic exposure (AUC) by 52% compared to administration alone. No data are available for use with other, less potent CYP450 3A4 or P-gp inducers.

MANAGEMENT: Caution is advised when bedaquiline is used in combination with inducers of CYP450 3A4 due to the potential for reduced antimycobacterial effect.

Drug and food interactions

Moderate

bedaquiline food

Applies to: bedaquiline

Food significantly increases the absorption of bedaquiline. Therefore, you should take each dose of bedaquiline with food. Taking it on an empty stomach may lead to inadequate blood levels and reduced effectiveness of the medication in treating tuberculosis. Avoid alcohol during treatment with bedaquiline, as it may increase the risk of liver damage. You should seek immediate medical attention if you develop signs and symptoms of liver damage such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, light colored stools, and yellowing of the skin or eyes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer